earnings
confidence high
sentiment positive
materiality 0.80
Tarsus Q1 net loss $20.2M; TP-03 hits all endpoints in Saturn-2 Phase 3
Tarsus Pharmaceuticals, Inc.
2022-Q1 EPS reported
-$0.98
revenue$539,000
- Q1 net loss $20.2M vs net income $10.4M YoY; license revenue $0.5M vs $33.4M.
- TP-03 met primary and all secondary endpoints in Saturn-2 Phase 3 for Demodex blepharitis; NDA submission H2 2022.
- Cash $175.3M at March 31; completed $71M net equity raise in May; cash runway into at least 2026.
- TP-05 Phase 1b Callisto data expected H2 2022; TP-04 Phase 2 for rosacea planned.